ClinicalTrials.gg
Status unknownNCT02113774Updated Apr 15, 2014

The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients

A Phase 4 interventional study of antimicrobial treatment according to in-vitro susceptibility in Urinary Tract Infection, Bacteriuria and Renal Transplantation, sponsored by Rabin Medical Center. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-15.

Primary conditionBacteriuriaRegistry: Urinary Tract InfectionsReclassifiedWhy we changed it
Registry
Urinary Tract Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bacteriuria
Why
  1. The study's listed conditions name Bacteriuria, a narrower term within Urinary Tract Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Rabin Medical Center · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2014), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Study summary

The investigators hypothesize that antibiotic therapy for asymptomatic bacteriuria in renal transplant patients does not have impact on the development of symptomatic urinary tract infection (UTI) or progression of renal impairment in patients during the first year after transplantation.

02

Conditions studied

  • Urinary Tract Infection
  • Bacteriuria
  • Renal Transplantation

Browse trials for

03

In context

Bacteriuria Reclassified

51 studies on the registry are indexed under Bacteriuria; 3 are open to participants now.

Browse Bacteriuria studies →

Lead sponsor

Rabin Medical Center is the lead sponsor of 393 studies on the registry; 30 are open to participants now.

Compared within Bacteriuria, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Tract Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are ≥1 month and ≤ 12 months after renal transplantation.
  • Positive urine culture defined as ≥ 105 colony forming units (CFU) per milliliter of a known single pathogen.

Exclusion criteria

Exclusion Criteria:

  • Any one of the following signs and symptoms: fever, abdominal pain, dysuria, frequency, urgency, flank pain, costovertebral-angel tenderness or tenderness over the transplanted kidney
  • Active infections in another site
  • Leucocytosis (WBC >18.000K/micl) or leucopenia (WBC \< 3.000 K/micl)
  • Elevation of serum creatinine of more than 15% of its baseline level
  • Obstructive or other urological complications following transplantation as known foreign device (stent/double-J-Cath, any catheter) in the urinary tract system, known obstruction of the transplanted kidney, indwelling or intermittent catheterization
  • Pregnant or lactating women.
  • Candidates to invasive urologic procedures.
  • Inability to return for regular follow up.
  • Previous enrollment in this study.
  • Patients who incapable of giving .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment

Study arms

  • No intervention
    no therapy
  • Active comparator
    antimicrobial treatment according to in-vitro susceptibility

    Other: antimicrobial treatment according to in-vitro susceptibility

Interventions

  • Otherantimicrobial treatment according to in-vitro susceptibility
06

What researchers measure

Primary outcomes

  1. development of symptomatic urinary tract infection

    Time frame: 30 days

Secondary outcomes

  1. 25% reduction in estimated glomerular filtration rate (eGFR)

    Time frame: 1 year

Other outcomes

  1. graft loss

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02113774
Responsible party
Ruth Rahamimov (head of transplant investigator service, Rabin Medical Center) — Principal investigator
First posted
Apr 15, 2014
Start date
Apr 2014
Primary completion
Apr 2019 (estimated)
Last update
Apr 15, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion